Hazel Player
GlaxoSmithKline
2 Papers
18 Citations
Hazel Player is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Chemical synthesis. The author has an hindex of 2, co-authored 2 publications.
Chat about Author
Papers
Identification and optimisation of a novel series of pyrimidine based cyclooxygenase-2 (COX-2) inhibitors. Utilisation of a biotransformation approach.
Paul John Beswick,Andrew P. Blackaby,C. Bountra,Terry Brown,Kerry Browning,Ian B. Campbell,John Andrew Corfield,Robert Gleave,Steve B. Guntrip,Richard M. Hall,Sean J. Hindley,Paul F. Lambeth,Fiona S. Lucas,Neil Mathews,Alan Naylor,Hazel Player,Helen Susanne Price,Phillip J. Sidebottom,Nicholas L. Taylor,Graham Webb,Joanne O. Wiseman +20 more
TL;DR: Traditional synthetic chemistry is complemented with a biotransformations approach which efficiently provided access to an array of key target molecules in the treatment of chronic inflammatory pain.
20
Identification of 2,3-diaryl-pyrazolo[1,5-b]pyridazines as potent and selective cyclooxygenase-2 inhibitors.
Paul John Beswick,Sharon Bingham,C. Bountra,Terry Brown,Kerry Browning,Ian B. Campbell,Iain P. Chessell,Nick M. Clayton,Sue D. Collins,John Andrew Corfield,Stephen Barry Guntrip,Claudine Haslam,Paul F. Lambeth,Fiona S. Lucas,Neil Mathews,Graham Murkit,Alan Naylor,Neil Anthony Pegg,Elizabeth Pickup,Hazel Player,Helen Susanne Price,Alexander J. Stevens,Sharon C Stratton,Joanne O. Wiseman +23 more
TL;DR: GW406381 (8), currently undergoing clinical evaluation for the treatment of inflammatory pain is a member of a novel series of 2,3-diaryl-pyrazolo[1,5-b]pyridazine based cyclooxygenase-2 (COX-2) inhibitors, which have been shown to be highly potent and selective.